

## Gemcitabine and DOCETaxel Therapy<sup>i</sup> - 21 day

### INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Treatment of locally advanced unresectable or metastatic soft tissue sarcoma.	C49	00501a	Hospital

### TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Gemcitabine is administered on Day 1 and Day 8 and DOCETaxel on Day 8 of a 21 day cycles for up to 6 cycles or until disease progression or unacceptable toxicity develops.

Facilities to treat anaphylaxis MUST be present when the chemotherapy is administered.

Admin. Order	Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	1, 8	Gemcitabine	675mg/m <sup>2</sup>	IV	250ml 0.9% NaCl over 90 minutes	Every 21 days for up to six cycles
2	8	<sup>a</sup> DOCETaxel	75mg/m <sup>2</sup>	IV	250ml 0.9% NaCl over 60 minutes	Every 21 days for up to six cycles

<sup>a</sup>Concentration of final volume should be <0.74mg/ml  
Use non-PVC equipment

### ELIGIBILITY:

- Indication as above
- ECOG 0-2

### EXCLUSIONS:

- Hypersensitivity to DOCETaxel, gemcitabine or any of the excipients
- Pregnancy
- Breast feeding

### PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist

### TESTS:

#### Baseline tests:

- FBC, renal and liver profile

NCCP Regimen: Gemcitabine and DOCETaxel Therapy	Published: 13/08/2018 Review: 30/07/2025	Version number: 2
Tumour Group: Sarcoma NCCP Regimen Code: 00501	ISMO Contributor: Dr Michael McCarthy, Prof Maccon Keane	Page 1 of 6

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*

- Bone profile

**Regular tests:**

- FBC, renal and liver profile prior to each cycle

**Disease monitoring:**

Disease monitoring should be in line with the patient's treatment plan and any other tests as directed by the supervising Consultant.

## DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.

**Table 1: Dose reduction levels for gemcitabine and DOCetaxel**

Starting Dose	Gemcitabine 675mg/m <sup>2</sup>	DOCetaxel 75mg/m <sup>2</sup>
Level -1	540 mg/m <sup>2</sup>	60 mg/m <sup>2</sup>
Level -2	450 mg/m <sup>2</sup>	50 mg/m <sup>2</sup>
Level-3	Discontinue	Discontinue

**Haematological:**

**Table 2: Dose modifications for haematological toxicity**

Day	ANC (x10 <sup>9</sup> /L)		Platelets (x10 <sup>9</sup> /L)	Dose
1	≥1	And	≥100	100%
	<1	and/or	<100	Delay for 1 week or until recovery
8	≥1	and	≥75	100%
	<1	and/or	<75	Delay for one week, if recovered sufficiently by day 15, the gemcitabine and DOCetaxel can be administered but with a dose reduction as indicated in the table 1 for all subsequent cycles
<b>Febrile Neutropenia</b>				
<b>1<sup>st</sup> occurrence</b>				Hold chemotherapy for remainder of cycle and consider addition of GCSF to subsequent cycles. Consider dose reduction by 1 dose level (Table 1)
<b>2<sup>nd</sup> occurrence</b>				

NCCP Regimen: Gemcitabine and DOCetaxel Therapy	Published: 13/08/2018 Review: 30/07/2025	Version number: 2
Tumour Group: Sarcoma NCCP Regimen Code: 00501	ISMO Contributor: Dr Michael McCarthy, Prof Maccon Keane	Page 2 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## Renal and Hepatic Impairment:

**Table 3: Dose modifications in renal and hepatic impairment**

Drug	Renal Impairment		Hepatic Impairment					
	DOCetaxel	No data available in patients with severely impaired renal function		<b>Serum Bilirubin</b>		<b>AST and/or ALT</b>		<b>Alkaline Phosphatase</b>
					> 1.5 ULN	and	> 2.5 ULN	75 mg/m <sup>2</sup>
> ULN				and/or	> 3.5 ULN (AST and ALT)	and	> 6 ULN	Stop treatment unless strictly indicated and should be discussed with a Consultant.
Gemcitabine	<b>Cr Cl (ml/min)</b>	<b>Dose</b>	AST elevations do not seem to cause dose limiting toxicities.					
	>30	100%						
	<30	Consider dose reduction. Clinical decision						

## Management of adverse events:

**Table 4: Dose Modifications for Adverse Events**

Adverse reactions	Recommended dose modification
Grade 2 peripheral neuropathy 1 <sup>st</sup> occurrence 2 <sup>nd</sup> occurrence	Reduce dose of gemcitabine and DOCetaxel by 1 dose level Reduce dose of gemcitabine and DOCetaxel by 1 dose level
Grade ≥3 Non haematological toxicities	Withhold treatment until toxicity resolved to Grade ≤1 and then reduce dose by 1 level

## SUPPORTIVE CARE:

**EMETOGENIC POTENTIAL:** Low (Refer to local policy).

## PREMEDICATIONS:

- Dexamethasone 8 mg PO twice daily for 3 days, starting one day prior to each DOCetaxel administration (day 7) unless contraindicated. Patient must receive minimum of 3 doses pre-treatment.
- *Consideration may be given, at the discretion of the prescribing consultant, to the use of a single dose of dexamethasone 20mg IV immediately before chemotherapy where patients have missed*

NCCP Regimen: Gemcitabine and DOCetaxel Therapy	Published: 13/08/2018 Review: 30/07/2025	Version number: 2
Tumour Group: Sarcoma NCCP Regimen Code: 00501	ISMO Contributor: Dr Michael McCarthy, Prof Maccon Keane	Page 3 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

taking the oral premedication dexamethasone as recommended by the manufacturer (5,6)

## OTHER SUPPORTIVE CARE:

Prophylactic G-CSF may be used to mitigate the risk of haematological toxicities G-CSF

## ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia:** Most frequent adverse reaction. Fever or other evidence of infection must be assessed promptly and treated appropriately. DOCEtaxel should be administered when the neutrophil count is  $>1.5 \times 10^9$  cells/L.

### Gemcitabine

- **Renal Toxicity:** Irreversible renal failure associated with hemolytic uremic syndrome may occur (rare) with gemcitabine. Use caution with pre-existing renal dysfunction.
- **Pulmonary Toxicity:** Acute shortness of breath may occur with gemcitabine. Discontinue treatment with gemcitabine if drug-induced pneumonitis is suspected.
- **Cardiovascular:** Due to the risk of cardiac and/or vascular disorders with gemcitabine, particular caution must be exercised with patients presenting a history of cardiovascular events.

### DOCEtaxel

- **Fluid Retention:** Dexamethasone premedication must be given prior to administration of DOCEtaxel to reduce the incidence and severity of fluid retention. It can also reduce the severity of the hypersensitivity reaction.
- **Hypersensitivity Reactions:** Patients should be observed closely for hypersensitivity reactions especially during the first and second infusions. Hypersensitivity reactions may occur within a few minutes following the initiation of the infusion of DOCEtaxel, thus facilities for the treatment of hypotension and bronchospasm should be available. If hypersensitivity reactions occur, minor symptoms such as flushing or localized cutaneous reactions do not require interruption of therapy. However, severe reactions, such as severe hypotension, bronchospasm or generalised rash/erythema require immediate discontinuation of DOCEtaxel and appropriate therapy. Patients who have developed severe hypersensitivity reactions should not be re-challenged with DOCEtaxel.
- **Extravasation:** DOCEtaxel causes pain and tissue necrosis if extravasated. **(Refer to local extravasation guidelines).**
- **Hepatic Dysfunction:** DOCEtaxel undergoes hepatic metabolism. Hepatic dysfunction (particularly elevated AST) may lead to increased toxicity and usually requires a dose reduction.

## DRUG INTERACTIONS:

- Risk of drug interactions causing increased concentrations of DOCEtaxel with CYP3A inhibitors. Patients should also be counselled with regard to consumption of grapefruit juice.
- Risk of drug interactions causing decreased concentrations of DOCEtaxel with CYP3A inducers

NCCP Regimen: Gemcitabine and DOCEtaxel Therapy	Published: 13/08/2018 Review: 30/07/2025	Version number: 2
Tumour Group: Sarcoma NCCP Regimen Code: 00501	ISMO Contributor: Dr Michael McCarthy, Prof Maccon Keane	Page 4 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

- Current drug interaction databases should be consulted for more information.

## ATC CODE:

DOCEtaxel L01CD02  
Gemcitabine L01BC05

## REFERENCES:

1. Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. *Lancet Oncol.* 2017 Oct;18(10):1397–410.
2. University College London. GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas [Internet]. Available from: [https://www.ctc.ucl.ac.uk/TrialDocuments/Uploaded/GeDDiS%20Protocol%20v8.0%2022Mar2016\\_06062017\\_0.pdf](https://www.ctc.ucl.ac.uk/TrialDocuments/Uploaded/GeDDiS%20Protocol%20v8.0%2022Mar2016_06062017_0.pdf)
3. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network. Available at <http://londoncancer.org/media/65600/renal-impairment-dosage-adjustment-for-cytotoxics.pdf>
4. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009; North London Cancer Network. Available at <http://londoncancer.org/media/65594/hepatic-impairment-dosage-adjustment-for-cytotoxics.pdf>
5. Chouhan et al. Single premedication dose of dexamethasone 20mg IV before DOCEtaxel administration. *J Oncol Pharm Practice* 2010;17(3): 155–159
6. Rogers ES et al. Efficacy and safety of a single dose of dexamethasone pre DOCEtaxel treatment: The Auckland experience. *Annals of Oncology* (2014) 25 (suppl\_4): iv517-iv541
7. Taxotere® Summary of Product Characteristics. Accessed July 2020 Available at : <https://www.medicines.ie/medicines/taxotere-20-mg-1-ml-concentrate-for-solution-for-infusion-33944/smpc>
8. Gemcitabine 40 mg/ml Concentrate for Solution for Infusion Summary of Product Characteristics Accessed July 2020. Available at [https://www.hpra.ie/img/uploaded/swedocuments/Licence\\_PA2059-039-005\\_13022020104725.pdf](https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2059-039-005_13022020104725.pdf)

Version	Date	Amendment	Approved By
1	13/08/2018		Dr Michael McCarthy
2	30/07/2020	Standardisation of treatment table Updated exclusion criteria Standardisation of pre-medication Updated adverse events section	Prof Maccon Keane

Comments and feedback welcome at [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie).

NCCP Regimen: Gemcitabine and DOCEtaxel Therapy	Published: 13/08/2018 Review: 30/07/2025	Version number: 2
Tumour Group: Sarcoma NCCP Regimen Code: 00501	ISMO Contributor: Dr Michael McCarthy, Prof Maccon Keane	Page 5 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

---

<sup>i</sup> This regimen is outside its licensed indication in Ireland. Patients should be informed of the unlicensed nature of this indication and consented to treatment in line with the hospital’s policy on the use of unlicensed medication and unlicensed or “off label” indications. Prescribers should be aware of their responsibility in communicating any relevant information to the patient and also in ensuring that the unlicensed or “off label” indication has been acknowledged by the hospital’s Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.

NCCP Regimen: Gemcitabine and DOCEtaxel Therapy	Published: 13/08/2018 Review: 30/07/2025	Version number: 2
Tumour Group: Sarcoma NCCP Regimen Code: 00501	ISMO Contributor: Dr Michael McCarthy, Prof Maccon Keane	Page 6 of 6

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE’s terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*